Perioperative Immunotherapy for NSCLC (ECTOP-1030)

Summary

This trial is a randomized, multicenter, open label phase II clinical study. The main objective is to evaluate the efficacy of three perioperative immunotherapy modalities (atezolizumab adjuvant therapy, nivolumab neoadjuvant therapy, pembrolizumab neoadjuvant+adjuvant therapy) in early-stage resectable NSCLC patients. The enrolled patients are randomly assigned in a 1:1:1 ratio to receive relevant treatment in the three perioperative immunotherapy groups mentioned above, and undergoing short-term pathological efficacy evaluation and long-term prognosis follow-up after surgery.

Timeline

Start

2024-09-01

Primary completion

2026-09-01

Completion

2029-09-01

Outcome

Outcome not reported

Stopped: “This trial has not been initiated”

Drugs

Indications